Prognostic impact of prostate-specific membrane antigen positron emission tomography (PSMA PET) staging for clinically node-positive prostate cancer

被引:5
作者
Leow, Boon Yang Jerome [1 ,5 ]
Eade, Thomas [1 ,2 ]
Hruby, George [2 ]
Lieng, Hester [1 ]
Hsiao, Edward [3 ]
Brown, Chris [2 ,4 ]
Kneebone, Andrew [1 ,2 ]
机构
[1] Gosford Hosp, Cent Coast Canc Ctr, Gosford, NSW, Australia
[2] Royal North Shore Hosp, Northern Sydney Canc Ctr, Radiat Oncol Unit, Sydney, NSW, Australia
[3] Royal North Shore Hosp, Dept Nucl Med & PET, Sydney, NSW, Australia
[4] Univ Sydney, Clin Trials Ctr, Natl Hlth & Med Res Council, Sydney, NSW, Australia
[5] Cent Coast Canc Ctr, Gosford, NSW 2250, Australia
关键词
PET imaging; prognosis; prostatic neoplasm; staging; RADIATION-THERAPY; FREE SURVIVAL; RADIOTHERAPY;
D O I
10.1111/1754-9485.13655
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Introduction: In the current American Joint Committee on Cancer staging system, patients with pelvic nodal metastases are considered stage IV prostate cancer. This study aims to investigate whether men with prostate-specific membrane antigen positron emission tomography (PSMA PET)-detected pelvic node-positive prostate cancer at diagnosis have a better outcome compared to men with node-positive disease identified on conventional imaging. Methods: This is a retrospective cohort study comparing the outcomes of men with node-positive prostate cancer and disease confined to the pelvis, staged with conventional versus PSMA PET imaging. Men had to be treated definitively with a combination of androgen deprivation therapy and radiation treatment to the prostate and pelvic lymph nodes. Kaplan-Meier and Cox regression analysis was used to compare biochemical failure-free survival (BFFS) and overall survival (OS). Results: Seventy-six men with nodal metastases confined to the pelvis were identified. Fifty-one were detected with PSMA PET while 25 were staged with conventional imaging. PSMA PET staged patients had a lower proportion of Gleason 8-10 disease (78% vs. 96%) as well as a lower median prostate-specific antigen (11 ng/mL vs. 26 ng/mL). BFFS at 4 years was 72% with PSMA PET-detected node-positive disease vs. 38% with conventionally detected node-positive disease. Four-year OS was 93% with PSMA PET staged patients vs. 76% with conventionally staged patients. On multivariate analysis, the PSMA PET staged group was associated with improved BFFS (Adjusted HR = 3.00, 95% CI 1.43, 6.29, P = 0.004) and OS (Adjusted HR = 5.81, 95% CI 1.43, 23.7, P = 0.007). Conclusion: Men with PSMA PET-detected node-positive prostate cancer confined to the pelvis have significantly better biochemical control and survival compared to those with node-positive pelvic disease identified through conventional staging.
引用
收藏
页码:721 / 728
页数:8
相关论文
共 23 条
[1]   The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging [J].
Amin, Mahul B. ;
Greene, Frederick L. ;
Edge, Stephen B. ;
Compton, Carolyn C. ;
Gershenwald, Jeffrey E. ;
Brookland, Robert K. ;
Meyer, Laura ;
Gress, Donna M. ;
Byrd, David R. ;
Winchester, David P. .
CA-A CANCER JOURNAL FOR CLINICIANS, 2017, 67 (02) :93-99
[2]   Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol [J].
Attard, Gerhardt ;
Murphy, Laura ;
Clarke, Noel W. ;
Cross, William ;
Jones, Robert J. ;
Parker, Christopher C. ;
Gillessen, Silke ;
Cook, Adrian ;
Brawley, Chris ;
Amos, Claire L. ;
Atako, Nafisah ;
Pugh, Cheryl ;
Buckner, Michelle ;
Chowdhury, Simon ;
Malik, Zafar ;
Russell, J. Martin ;
Gilson, Clare ;
Rush, Hannah ;
Bowen, Jo ;
Lydon, Anna ;
Pedley, Ian ;
O'Sullivan, Joe M. ;
Birtle, Alison ;
Gale, Joanna ;
Srihari, Narayanan ;
Thomas, Carys ;
Tanguay, Jacob ;
Wagstaff, John ;
Das, Prantik ;
Gray, Emma ;
Alzoueb, Mymoona ;
Parikh, Omi ;
Robinson, Angus ;
Syndikus, Isabel ;
Wylie, James ;
Zarkar, Anjali ;
Thalmann, George ;
de Bono, Johann S. ;
Dearnaley, David P. ;
Mason, Malcolm D. ;
Gilbert, Duncan ;
Langley, Ruth E. ;
Millman, Robin ;
Matheson, David ;
Sydes, Matthew R. ;
Brown, Louise C. ;
Parmar, Mahesh K. B. ;
James, Nicholas D. .
LANCET, 2022, 399 (10323) :447-460
[3]   Common Iliac Node-Positive Prostate Cancer Treated With Curative Radiation Therapy: N1 or M1a? [J].
Chopade, Pradnya ;
Maitre, Priyamvada ;
David, Sam ;
Panigrahi, Gitanjali ;
Singh, Pallavi ;
Phurailatpam, Reena ;
Murthy, Vedang .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (04) :711-717
[4]   Results of a Prospective Dose Escalation Study of Linear Accelerator-Based Virtual Brachytherapy (BOOSTER) for Prostate Cancer; Virtual HDR Brachytherapy for Prostate Cancer [J].
Eade, Thomas ;
Hruby, George ;
Booth, Jeremy ;
Bromley, Regina ;
Guo, Lesley ;
O'Toole, Andrew ;
Le, Andrew ;
Wu, Kenny ;
Whitaker, May ;
Rasiah, Krishan ;
Chalasani, Venu ;
Vass, Justin ;
Kwong, Carolyn ;
Atyeo, John ;
Kneebone, Andrew .
ADVANCES IN RADIATION ONCOLOGY, 2019, 4 (04) :623-630
[5]   The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma Definition of Grading Patterns and Proposal for a New Grading System [J].
Epstein, Jonathan I. ;
Egevad, Lars ;
Amin, Mahul B. ;
Delahunt, Brett ;
Srigley, John R. ;
Humphrey, Peter A. .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2016, 40 (02) :244-252
[6]   Impact of staging with 18F-FDG-PET on outcome of patients with stage III non-small cell lung cancer:: PET identifies potential survivors [J].
Eschmann, S. M. ;
Friedel, G. ;
Paulsen, F. ;
Reimold, M. ;
Hehr, T. ;
Scheiderbauer, J. ;
Budach, W. ;
Kotzerke, J. ;
Bares, R. .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 (01) :54-59
[7]   NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Postoperative Prostate Cancer [J].
Hall, William A. ;
Paulson, Eric ;
Davis, Brian J. ;
Spratt, Daniel E. ;
Morgan, Todd M. ;
Dearnaley, David ;
Tree, Alison C. ;
Efstathiou, Jason A. ;
Harisinghani, Mukesh ;
Jani, Ashesh B. ;
Buyyounouski, Mark K. ;
Pisansky, Thomas M. ;
Tran, Phuoc T. ;
Karnes, R. Jeffrey ;
Chen, Ronald C. ;
Cury, Fabio L. ;
Michalski, Jeff M. ;
Rosenthal, Seth A. ;
Koontz, Bridget F. ;
Wong, Anthony C. ;
Nguyen, Paul L. ;
Hope, Thomas A. ;
Feng, Felix ;
Sandler, Howard M. ;
Lawton, Colleen A. F. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 109 (01) :174-185
[8]   Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study [J].
Hofman, Michael S. ;
Lawrentschuk, Nathan ;
Francis, Roslyn J. ;
Tang, Colin ;
Vela, Ian ;
Thomas, Paul ;
Rutherford, Natalie ;
Martin, Jarad M. ;
Frydenberg, Mark ;
Shakher, Ramdave ;
Wong, Lih-Ming ;
Taubman, Kim ;
Lee, Sze Ting ;
Hsiao, Edward ;
Roach, Paul ;
Nottage, Michelle ;
Kirkwood, Ian ;
Hayne, Dickon ;
Link, Emma ;
Marusic, Petra ;
Matera, Anetta ;
Herschtal, Alan ;
Iravani, Amir ;
Hicks, Rodney J. ;
Williams, Scott ;
Murphy, Declan G. .
LANCET, 2020, 395 (10231) :1208-1216
[9]   68Ga-PSMA-PET/CT staging prior to definitive radiation treatment for prostate cancer [J].
Hruby, George ;
Eade, Thomas ;
Emmett, Louise ;
Ho, Bao ;
Hsiao, Ed ;
Schembri, Geoff ;
Guo, Linxin ;
Kwong, Carolyn ;
Hunter, Julia ;
Byrne, Keelan ;
Kneebone, Andrew .
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 (04) :343-346
[10]   Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer Data From Patients in the Control Arm of the STAMPEDE Trial [J].
James, Nicholas D. ;
Spears, Melissa R. ;
Clarke, Noel W. ;
Dearnaley, David P. ;
Mason, Malcolm D. ;
Parker, Christopher C. ;
Ritchie, Alastair W. S. ;
Russell, J. Martin ;
Schiavone, Francesca ;
Attard, Gerhardt ;
de Bono, Johann S. ;
Birtle, Alison ;
Engeler, Daniel S. ;
Elliott, Tony ;
Matheson, David ;
O'Sullivan, Joe ;
Pudney, Delia ;
Srihari, Narayanan ;
Wallace, Jan ;
Barber, Jim ;
Syndikus, Isabel ;
Parmar, Mahesh K. B. ;
Sydes, Matthew R. .
JAMA ONCOLOGY, 2016, 2 (03) :348-357